Clinical Trial Update: Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers. [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pharmacokinetics, bioequivalence, and safety of two Trimedat formulations (76.95 mg orally disintegrating tablet and 100 mg tablet) in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Dyskinesia
• Cholelithiasis
• Gastroesophageal Reflux Disease
• Irritable Bowel Syndrome
• Postcholecystectomy Syndrome

Drugs mentioned

• Trimedat 100 mg tablet (Trimebutine)
• Trimedat 76.95 mg orally disintegrating tablet (Trimebutine)

Snippet

Sponsor: Valenta Pharm JSC | Conditions: Irritable Bowel Syndrome, Gallstone Disease | Phase 1 | Status: RECRUITING